


PHARMACEUTICAL 2023



NGM BIOPHARMACEUTICALS INC Rank 143 of 446





PHARMACEUTICAL 2023



NGM BIOPHARMACEUTICALS INC Rank 143 of 446

The relative strengths and weaknesses of NGM BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NGM BIOPHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of NGM BIOPHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 160%, being 117% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	288,859
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	47,842
Liabilities, Non-Current	0
Other Assets	10,047
Other Compr. Net Income	-173
Other Expenses	0
Other Liabilities	0
Other Net Income	3,582
Other Revenues	55,333
Property and Equipment	8,496
Research and Development	181,067
Selling, General and Administrative Expense	40,515

Output Variable	Value in 1000 USD
Assets	307,402
Liabilities	47,842
Expenses	221,582
Revenues	55,333
Stockholders Equity	259,560
Net Income	-162,667
Comprehensive Net Income	-162,754
Economic Capital Ratio	160%

